文献速递胸部肿瘤泌尿男性生殖肿瘤

Birabresib在晚期实体瘤中的Ib期试验

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
PubMed 文献 · J Clin Oncol · 2018-05-07

Birabresib是一种BET蛋白抑制剂,在去势抵抗性前列腺癌、NUT中线癌和非小细胞肺癌患者中评估安全性、疗效和药代动力学。推荐的II期剂量为80mg每日一次连续给药,暴露呈剂量比例增加,在NMC中观察到临床活性。

要点

  • 推荐II期剂量为80mg每日一次连续给药。
  • 剂量限制性毒性包括血小板减少、转氨酶/高胆红素血症。
  • NMC患者中观察到部分缓解,持续时间1.4至8.4个月。

核心结论

  • Birabresib在选定实体瘤中的推荐II期剂量为80mg每日一次连续给药。
  • Birabresib暴露呈剂量比例增加,安全性良好,在NMC中观察到临床活性。

研究设计与样本

  • 患者接受birabresib每日一次,起始剂量80mg连续(队列A)或100mg连续7天(队列B),21天为一周期。

主要发现

  • 46例可评估患者中,26例去势抵抗性前列腺癌,10例NMC,10例非小细胞肺癌。
  • 队列A中19例可评估患者有4例(21%)在80mg每日一次时发生DLT(3级血小板减少3例,ALT/高胆红素血症1例)。
  • 队列A中100mg每日一次组3例中有2例发生DLT(2级厌食和恶心导致治疗延迟>7天1例,4级血小板减少1例)。
  • 队列B未发生DLT。
  • 46例患者中38例(83%)发生治疗相关不良事件(腹泻17例[37%],恶心17例[37%],厌食14例[30%],呕吐12例[26%],血小板减少10例[22%])。

关键数值与推荐

  • 推荐的II期剂量为80mg每日一次连续给药。
  • 药代动力学分析显示birabresib暴露呈剂量比例增加且吸收迅速。

临床怎么用

  • 在选定实体瘤中,birabresib的II期推荐剂量为80mg每日一次连续给药。
  • 未来研究应考虑间歇给药方案以可能减轻慢性给药的毒性。

局限性

  • 样本量小,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Birabresib (MK-8628/OTX015) is a first-in-class bromodomain inhibitor with activity in select hematologic tumors. Safety, efficacy, and pharmacokinetics of birabresib were evaluated in patients with castrate-resistant prostate cancer, nuclear protein in testis midline carcinoma (NMC), and non-small-cell lung cancer in this phase Ib study. PATIENTS AND METHODS: Forty-seven patients were enrolled to receive birabresib once daily at starting doses of 80 mg continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles using a parallel dose escalation 3 + 3 design. The primary objective was occurrence of dose-limiting toxicities (DLTs) and determination of the recommended phase II dose. RESULTS: Of 46 treated patients, 26 had castrate-resistant prostate cancer, 10 NMC, and 10 non-small-cell lung cancer. For cohort A, four of 19 (21%) evaluable patients had DLTs at 80 mg once daily (grade 3 thrombocytopenia [n = 3], ALT/hyperbilirubinemia [n = 1]) and two of three had DLTs at 100 mg once daily (grade 2 anorexia and nausea with treatment delay > 7 days [n = 1], grade 4 thrombocytopenia [n = 1]). No DLTs occurred in cohort B. Of 46 patients, 38 (83%) had treatment-related adverse events (diarrhea, 17 [37%]; nausea, 17 [37%]; anorexia, 14 [30%]; vomiting, 12 [26%]; thrombocytopenia 10 [22%]). Three patients with NMC (80 mg once daily) had a partial response (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) with duration of 1.4 to 8.4 months. Pharmacokinetic analysis indicated a dose-proportional increase in birabresib exposure and rapid absorption. CONCLUSION: The recommended phase II dose of birabresib in patients with select solid tumors is 80 mg once daily with continuous dosing. Birabresib has dose-proportional exposure and a favorable safety profile, with clinical activity observed in NMC. Future studies of birabresib must consider intermittent scheduling to possibly mitigate the toxicities of chronic dosing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lewin J, Soria JC, Stathis A, et al. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. J Clin Oncol. 2018. PMID: 29733771. doi:10.1200/JCO.2018.78.2292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。